TITLE

Postprandial Hyperglycemia and Glycemic Variability

AUTHOR(S)
STANDL, EBERHARD; SCHNELL, OLIVER; CERIELLO, ANTONIO
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS120
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of this article is to evaluate the pros and cons of a specific impact of postprandial hyperglycemia and glycemic variability on the--mainly cardiovascular (CV)--complications of diabetes, above and beyond the average blood glucose (BG) as measured by HbA1c or fasting plasma glucose (FPG). The strongest arguments in favor of this hypothesis come from impressive pathophysiological studies, also in the human situation. Measures of oxidative stress and endothelial dysfunction seem to be especially closely related to glucose peaks and even more so to fluctuating high and low glucose concentrations and can be restored to normal by preventing those glucose peaks or wide glucose excursions. The epidemiological evidence, which is more or less confined to postprandial hyperglycemia and postglucose load glycemia, is also rather compelling in favor of the hypothesis, although certainly not fully conclusive as there are also a number of conflicting results. The strongest cons are seen in the missing evidence as derived from randomized prospective intervention studies targeting postprandial hyperglycemia longer term, i.e., over several years, and seeking to reduce hard CV end points. In fact, several such intervention studies in men have recently failed to produce the intended beneficial outcome results. As this evidence by intervention is, however, key for the ultimate approval of a treatment concept in patients with diabetes, the current net balance of attained evidence is not in favor of the hypothesis here under debate, i.e., that we should care about postprandial hyperglycemia and glycemic variability. The absence of a uniformly accepted standard of how to estimate these parameters adds a further challenge to this whole debate.
ACCESSION #
61967998

 

Related Articles

  • Methylglyoxal Impairs the Insulin Signaling Pathways Independently of the Formation of Intracellular Reactive Oxygen Species. Riboulet-Chavey, Audrey; Pierron, Anne; Durand, Isabelle; Murdaca, Joseph; Giudicelli, Jean; Van Obberghen, Emmanuel // Diabetes;May2006, Vol. 55 Issue 5, p1289 

    Nonenzymatic glycation is increased in diabetes and leads to elevated levels of advanced glycation end products (AGEs), which link hyperglycemia to the induction of insulin resistance. In hyperglycemic conditions, intracellularly formed α-ketoaldehydes, such as methylglyoxal, are an essential...

  • Glycemic Variability: How Do We Measure It and Why Is It Important? Sunghwan Suh; Jae Hyeon Kim // Diabetes & Metabolism Journal;Aug2015, Vol. 39 Issue 4, p273 

    Chronic hyperglycemia is the primary risk factor for the development of complications in diabetes mellitus (DM); however, it is believed that frequent or large glucose fluctuations may independently contribute to diabetes-related complications. Postprandial spikes in blood glucose, as well as...

  • The Acute Effect of Clamped Hyperglycemia on the Urinary Excretion of Inflammatory Cytokines/Chemokines in Uncomplicated Type 1 Diabetes. CHERNEY, DAVID Z.I.; SCHOLEY, JAMES W.; SOCHETT, ETIENNE; BRADLEY, TIMOTHY J.; REICH, HEATHER N. // Diabetes Care;Jan2011, Vol. 34 Issue 1, p177 

    OBJECTIVE-- Acute glycemic variability contributes to diabetic complications potentially through induction of inflammation. Our objective was to determine whether acute hyperglycemia affects urinary secretion of inflammatory cytokines/chemokines in humans with uncomplicated type 1 diabetes....

  • The Effect of Pioglitazone on the Liver. Gastaldelli, Amalia; Miyazaki, Yoshinori; Mahankali, Archana; Berria, Rachele; Pettiti, Maura; Buzzigoli, Emma; Ferrannini, Eleuterio; DeFronzo, Ralph A. // Diabetes Care;Oct2006, Vol. 29 Issue 10, p2275 

    OBJECTIVE -- Diabetic hyperglycemia results from insulin resistance of peripheral tissues and glucose overproduction due to increased gluconeogenesis (GNG). Thiazolidinediones (TZDs) improve peripheral insulin sensitivity, but the effect on the liver is less clear. The goal of this study was to...

  • Variability in the Relationship between Mean Plasma Glucose and HbA[sub 1c]: Implications for the Assessment of Glycemic Control. Kilpatrick, Eric S.; Rigby, Alan S.; Atkin, Stephen L. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA113 

    Previous studies have shown a single linear relationship between mean plasma glucose (MPG) and HbA[sub 1c]. This study has examined the relationship in the different treatment groups of patients with type 1 diabetes participating in the Diabetes Control and Complications Trial (DCCT). Seven...

  • A Link Between Hyperglycemia And Retinopathy.  // Countdown;Spring2006, Vol. 27 Issue 2, p6 

    The article reports on the relationship between hyperglycemia and retinopathy. A molecular link has been identified connecting high blood sugar levels inside cells to the initiation of diabetic retinopathy by a team of researchers led by Michael Brownlee. Methylglyyoxal turns on a gene...

  • Fasting Glucose and Diabetic Neuropathy. Rubin, Michael // Neurology Alert;Jul2009, Vol. 27 Issue 11, p82 

    Chronic Hyperglycemia results in retinopathy, nephropathy, and peripheral neuropathy. Although initial studies suggested that fasting plasma glucose (FPG) levels above 126 mg/dL resulted in a dramatic rise in the incidence of retinopathy, three large population-based studies subsequently...

  • Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial--Revisited. Lachin, John M.; Genuth, Saul; Nathan, David M.; Zinman, Bernard; Rutledge, Brandy N. // Diabetes;Apr2008, Vol. 57 Issue 4, p995 

    OBJECTIVE--The Diabetes Control and Complications Trial (Diabetes 44:968-983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis...

  • Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Calcutt, Nigel A.; Cooper, Mark E.; Kern, Tim S.; Schmidt, Ann Marie // Nature Reviews Drug Discovery;May2009, Vol. 8 Issue 5, p417 

    Long-term diabetes increases the likelihood of developing secondary damage to numerous systems, and these complications represent a substantial cause of morbidity and mortality. Establishing the causes of diabetes remains the key step towards eradicating the disease, but the prevention and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics